Metastatic lung adenocarcinoma related alpha-Fetoprotein elevation in a patient with HBV-related cirrhosis

Hamamci M., Karaahmet F., Akinci H., Kilincalp S., Acikgoz R., Coban S., ...More

ACTA GASTRO-ENTEROLOGICA BELGICA, vol.78, no.4, pp.441-442, 2015 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Letter
  • Volume: 78 Issue: 4
  • Publication Date: 2015
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.441-442
  • Ankara Yıldırım Beyazıt University Affiliated: Yes


HCC is the most common type of primary liver tumor. The Practice Guideline, AASLD, for HCC recommended surveillance of HBV carriers at high risk of HCC with US every 6-12 months. Laboratory surveillance option is the measurement of serum alpha-fetoprotein level which has long been used for the diagnosis of HCC. But, increased serum levels of alpha-fetoprotein are also seen in acute hepatitis, cirrhosis, and malignancies include yolk sac carcinoma, neuroblastoma, hepatoblastoma, gastric and lung carcinoma. Because of elevation alpha-fetoprotein in these malignancies, liver mass with an elevated alpha-fetoprotein does not directly indicate HCC. For these reason, clinicians evaluating patient with liver mass and HBV-related cirrhosis should be vigilant for other case of alpha-fetoprotein elevation.